📊 Score Breakdown
Offering Ability
90
Cash Runway
10
Float Risk
30
Warrant Exposure
15
Convertible Debt—
🌦️ Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
26%
📉 Score Deterioration
40%
• Score rose 20 points recently (worsening)
💰 Capital Raise
20%
• Active shelf registration ($250M, 287% of market cap)
💹 Market Data
Market Cap$87.03M
Shares Outstanding9.35M
Float5.83M
Cash$137.59M
Debt$13.90M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↓ 99.6% shares (2025Q4 vs prior)
3 institutional holders · 231.1K shares
#1
BARCLAYS PLC
150.0K shares
#2
REGENERON PHARMACEUTICALS, INC.
60.5K shares
#3
BANK OF AMERICA CORP /DE/
20.6K shares
📉 Short Interest
Short Interest587.8K
Days to Cover5.7
% of Float10.1%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL WARRANT
Dec 31, 2025
xbrl
XBRL CONVERTIBLE
Dec 31, 2020
8-K
8K EVENT
Apr 28, 2026
3
FORM3
Apr 13, 2026
4
INSIDER TRANSACTION
Apr 13, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for ACET
📊 ACET FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 ACET Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.